Oracle Corporation (ORCL)

Oracle is trading near the bottom of its 52-week range after a steep slide, but the analyst mood has turned more constructive. The stock closed up 3.18% in the latest session at $119.79, sitting 8% of the way up its 52-week range of $109.21 to $250.25. Stephens & Co. upgraded the stock to Overweight from Equal-Weight on November 2, 2026, and the analyst community remains heavily positive, with 33 of 40 current ratings at buy or strong buy. Against that, the trend is firmly down: the stock sits below its 50-day and 200-day moving averages ($138.49 and $155.12), and the one-year return is down 49.93%.

Stephens & Co. upgraded the stock to Overweight from Equal-Weight on November 2, 2026. Oppenheimer, Piper Sandler, Wells Fargo, Goldman Sachs and TD Cowen all kept their positive ratings between October 23 and October 29, 2026. Of 40 current ratings, 33 are buy or strong buy, 6 are hold and 1 is sell or strong sell. Three months ago the count was 36 buy ratings out of 44. The median 12-month target of $225.00 is 87.8% above the price, and even the lowest target of $110.00 is close to the current level. Analysts are clearly more positive than the price action, which makes the gap between the two the central question for the stock.

The stock fell 15.28% over the past month and 49.93% over the past year. The 14-day RSI is 41.9, which is in the neutral zone, and the MACD line is negative.

The trailing P/E is 18.21, a discount to peers and 48.1% below the sector median of 35.1. The price-to-sales ratio of 5.20 is 31.6% below the sector median of 7.6. Oracle beat EPS estimates in five of the last eight reports, and the September 10, 2026 report beat by 10.34%, with EPS of $1.92 against $1.74 expected. Even so, the stock fell 1.74% in the first session after that report, and it also fell after the June and December reports. Beats have not reliably lifted the price.

The net profit margin is 26.1%, the operating margin is 35.63% and return on equity is 41.19%, against a sector median of 13.4%. Debt is heavy, with a debt-to-equity ratio of 2.52. Analysts expect revenue to grow 34.3% this fiscal year, and the dividend yield is 1.67% on a $2.00 annual dividend. Insiders sold $2.1B of stock over the last 18 months, while open-market purchases totalled $3.6M. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than open-market buying.

The base case is that Oracle keeps trading in a wide, volatile range while the trend repairs slowly. For the trend to turn, the stock would first need to reclaim the 20-day EMA of $127.95 and then the 50-day SMA of $138.49, which would show that the recent bounce is holding. The analysts' median 12-month target of $225.00 sits well above the current price, and the range of targets runs from $110.00 to $400.00, so the gap between Wall Street's view and the market's current pricing is large. A sustained move above the 50-day SMA would strengthen the case for a recovery. A failure to hold the recent low would weaken it and put the 52-week low of $109.21 back in position. Fiscal-year estimates call for EPS growth of 6.8% this year and 35.7% next year, and delivering on those numbers is the main test.

Support sits at the 52-week low of $109.21, the nearest level below the price and the point where a fall would meet its first floor. Resistance comes first at the 20-day EMA of $127.95, followed by the 50-day SMA of $138.49, and then the 200-day SMA of $155.12. The 52-week high of $250.25 is the far ceiling. The 20-day EMA is the nearest hurdle, and a close above it would be the first sign that short-term momentum is improving. The 50-day SMA is the more important test, because the stock has been below it for a while.